Activin and Inhibin

GNE-274 is a non-degrader that is structurally related to GDC-0927 (ER degrader). GNE-274 does not induce ER turnover and functions as a partial ER agonist in breast cancer cell lines. GNE-274 increase chromatin accessibility at ER-DNA binding

GNE-274 is a non-degrader that is structurally related to GDC-0927 (ER degrader). GNE-274 does not induce ER turnover and functions as a partial ER agonist in breast cancer cell lines. GNE-274 increase chromatin accessibility at ER-DNA binding

GNE-274 is a non-degrader that is structurally related to GDC-0927 (ER degrader). GNE-274 does not induce ER turnover and functions as a partial ER agonist in breast cancer cell lines. GNE-274 increase chromatin accessibility at ER-DNA binding

GNE-3511 is an orally active bioavailable and brain-penetrant dual leucine zipper kinase (DLK) inhibitor with a K i of 0.5 nM. GNE-3511 can cross the blood-brain-barrier and can be used for the research of neurodegenerative diseasesIn VitroGNE-3511

GNE-3511 is an orally active bioavailable and brain-penetrant dual leucine zipper kinase (DLK) inhibitor with a K i of 0.5 nM. GNE-3511 can cross the blood-brain-barrier and can be used for the research of neurodegenerative diseasesIn VitroGNE-3511

GNE-3511 is an orally active bioavailable and brain-penetrant dual leucine zipper kinase (DLK) inhibitor with a K i of 0.5 nM. GNE-3511 can cross the blood-brain-barrier and can be used for the research of neurodegenerative diseasesIn VitroGNE-3511

GNE-3511 is an orally active bioavailable and brain-penetrant dual leucine zipper kinase (DLK) inhibitor with a K i of 0.5 nM. GNE-3511 can cross the blood-brain-barrier and can be used for the research of neurodegenerative diseasesIn VitroGNE-3511

GNE-3511 is an orally active bioavailable and brain-penetrant dual leucine zipper kinase (DLK) inhibitor with a K i of 0.5 nM. GNE-3511 can cross the blood-brain-barrier and can be used for the research of neurodegenerative diseasesIn VitroGNE-3511

GNE-375 is a potent and highly selective BRD9 inhibitor with an IC 50 of 5 nM. GNE-375 shows &gt:100-fold selective for BRD9 over BRD4 , TAF1, and CECR2 . GNE-375 decreases BRD9 binding to chromatinForm:SolidIC50&amp: Target:BRD9 5 nM (IC 50 ).

GNE-375 is a potent and highly selective BRD9 inhibitor with an IC 50 of 5 nM. GNE-375 shows &gt:100-fold selective for BRD9 over BRD4 , TAF1, and CECR2 . GNE-375 decreases BRD9 binding to chromatinForm:SolidIC50&amp: Target:BRD9 5 nM (IC 50 ).

GNE-375 is a potent and highly selective BRD9 inhibitor with an IC 50 of 5 nM. GNE-375 shows &gt:100-fold selective for BRD9 over BRD4 , TAF1, and CECR2 . GNE-375 decreases BRD9 binding to chromatinForm:SolidIC50&amp: Target:BRD9 5 nM (IC 50 ).

GNE-375 is a potent and highly selective BRD9 inhibitor with an IC 50 of 5 nM. GNE-375 shows &gt:100-fold selective for BRD9 over BRD4 , TAF1, and CECR2 . GNE-375 decreases BRD9 binding to chromatinIC50&amp: Target:BRD9 5 nM (IC 50 ).